TRACON

TRACON Pharmaceuticals Announces Reverse Stock Split

Retrieved on: 
Monday, April 8, 2024
TCON, TRACON, SAN, CUSIP, EQ, Therapy, Security (finance)

All stock options and warrants of the Company outstanding immediately prior to the reverse stock split have been proportionally adjusted.

Key Points: 
  • All stock options and warrants of the Company outstanding immediately prior to the reverse stock split have been proportionally adjusted.
  • No fractional shares of common stock will be issued as a result of the reverse stock split.
  • TRACON has chosen its transfer agent, Equiniti Trust Company, LLC (EQ), to act as exchange agent for the reverse stock split.
  • Stockholders owning shares via a bank, broker or other nominee will have their positions automatically adjusted to reflect the reverse stock split and will not be required to take further action in connection with the reverse stock split, subject to brokers’ particular processes.

Biocytogen Launches RenBiologics, A Sub-Brand Focused on Out-Licensing Fully Human Antibodies For Therapeutic Development

Retrieved on: 
Wednesday, January 24, 2024
Research, Infectious Diseases, Neurology, Cardiology, Biotechnology, Managed Care, Pharmaceutical, Health, Science, Oncology, Hook effect, DSM-IV codes, Therapy, Monoclonal antibody, Merck Group, ADC, TCR, TRACON, HKEX, Partnership, Infection, IND, Neurocrine, Medication, Antibody, Protein, PCC, Multinational corporation, Hansoh Pharmaceutical, Vaccine

RenBiologics business will cover out-licensing/co-development of the company’s extensive library of fully human antibodies, as well as licensing of RenMice®, the company’s fully human antibody/TCR discovery platforms.

Key Points: 
  • RenBiologics business will cover out-licensing/co-development of the company’s extensive library of fully human antibodies, as well as licensing of RenMice®, the company’s fully human antibody/TCR discovery platforms.
  • The RenBiologics logo features an antibody with human-centric design elements, highlighting Biocytogen's expertise in discovering fully human antibodies; the encircled design underscores the company’s dedication to becoming a global resource of fully human antibodies to expedite the development of novel antibody-based therapeutics.
  • Biocytogen’s fully human antibody sequences were generated by proprietary RenMice strains, each engineered to lack a certain drug target gene.
  • RenMice-derived fully human antibodies can be developed into novel therapies to treat numerous cancers, inflammatory and autoimmune diseases, infectious diseases, metabolic diseases, cardiovascular diseases, and neurological diseases.

Biocytogen Launches RenBiologics, A Sub-Brand Focused on Out-Licensing Fully Human Antibodies For Therapeutic Development

Retrieved on: 
Tuesday, January 23, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Clinical Trials, Hook effect, DSM-IV codes, Therapy, Monoclonal antibody, Merck Group, ADC, TCR, Multimedia, TRACON, HKEX, Partnership, Infection, IND, Neurocrine, Medication, Antibody, Protein, PCC, Multinational corporation, Hansoh Pharmaceutical, Vaccine

RenBiologics business will cover out-licensing/co-development of the company’s extensive library of fully human antibodies, as well as licensing of RenMice®, the company’s fully human antibody/TCR discovery platforms.

Key Points: 
  • RenBiologics business will cover out-licensing/co-development of the company’s extensive library of fully human antibodies, as well as licensing of RenMice®, the company’s fully human antibody/TCR discovery platforms.
  • The RenBiologics logo features an antibody with human-centric design elements, highlighting Biocytogen's expertise in discovering fully human antibodies; the encircled design underscores the company’s dedication to becoming a global resource of fully human antibodies to expedite the development of novel antibody-based therapeutics.
  • RenMice®-derived fully human antibodies can be developed into novel therapies to treat numerous cancers, inflammatory and autoimmune diseases, infectious diseases, metabolic diseases, cardiovascular diseases, and neurological diseases.
  • Biocytogen offers licensing and flexible partnering models for its RenMice fully human antibody/TCR discovery platforms.

TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment

Retrieved on: 
Monday, November 20, 2023
Documentation, PDP, Therapy, Research, SAN, Agreement, TCON, TRACON

SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform (PDP) to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced it has licensed its proprietary PDP of CRO-independent clinical research to a clinical stage biotech company for a $3.0 million upfront payment.

Key Points: 
  • SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform (PDP) to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced it has licensed its proprietary PDP of CRO-independent clinical research to a clinical stage biotech company for a $3.0 million upfront payment.
  • “We are excited to announce the first license of our PDP to a company that recognizes the value of internalizing its clinical operations to reap the benefits of CRO-independent clinical trial implementation that we enjoy at TRACON,” said Charles Theuer, M.D., Ph.D., TRACON’s Chief Executive Officer.
  • “We are now in a position to widely license our PDP to allow clinical stage biotechnology and pharmaceutical companies to transform their clinical operations with the expectation of potentially dramatic cost reductions and shorter clinical trial timelines.”
    Under the terms of the Agreement, TRACON granted a non-exclusive and non-transferable license of its PDP to the clinical stage biotech company for the design, conduct and administration of clinical trials and related research and development activities, including activities relating to regulatory filings, submissions and approvals.
  • A licensee can integrate TRACON’s configuration documentation with a widely-used software package, enabling validation and qualification of the software package, in conjunction with TRACON’s standard operation procedure documents, policies, work instructions, and clinical operation templates.

TRACON Pharmaceuticals Announces Enforcement Action to Collect Binding Arbitration Award from I-Mab Biopharma

Retrieved on: 
Thursday, June 15, 2023
SAN, Cayman, Therapy, High court, TRACON, TCON, Fine chemical, Cryptocurrency, Film industry

SAN DIEGO, June 15, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with other life science companies to develop and commercialize innovative products in the United States, today announced that it has commenced court proceedings in Hong Kong and the Cayman Islands to enforce an April 2023 arbitration award against I-Mab for approximately $23.0 million, plus interest.

Key Points: 
  • SAN DIEGO, June 15, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with other life science companies to develop and commercialize innovative products in the United States, today announced that it has commenced court proceedings in Hong Kong and the Cayman Islands to enforce an April 2023 arbitration award against I-Mab for approximately $23.0 million, plus interest.
  • On June 14, 2023, TRACON served I-Mab with an order of the High Court of the Hong Kong Special Administrative Region provisionally allowing TRACON to begin enforcing that award as soon as July 13, 2023 in Hong Kong.
  • “I-Mab issued a press release acknowledging that the arbitration award is final and binding, and stating that it would confirm the award promptly, so we are disappointed they are delinquent in paying the award,” said Charles Theuer, M.D., Ph.D., President and CEO of TRACON.
  • “We commenced these judicial proceedings to collect the full amount I-Mab owes, including accumulating interest.”

TRACON Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, May 10, 2023
CT, Therapy, Completeness, TRACON, IDMC, Patient, TCON, Ipilimumab, Doxorubicin, SAN, Research, LPC, Safety, Fine chemical, Pharmaceutical industry, Video game

Research and development expenses for the first quarter of 2023 were $5.0 million, compared to $3.0 million for the first quarter of 2022.

Key Points: 
  • Research and development expenses for the first quarter of 2023 were $5.0 million, compared to $3.0 million for the first quarter of 2022.
  • The increase was primarily related to envafolimab drug product purchased in the first quarter of 2023.
  • General and administrative expenses for the first quarter of 2023 were $2.3 million, compared to $6.5 million for the first quarter of 2022.
  • Net loss for the first quarter of 2023 was $8.5 million, compared to $9.5 million for the first quarter of 2022.

TRACON Pharmaceuticals Announces Arbitration Award in Dispute with I-Mab

Retrieved on: 
Tuesday, April 25, 2023
International, Therapy, TRACON, Clinical trial, CD73, ICC, SAN, TCON, Commerce, Fine chemical

I-Mab commenced arbitration in June 2020, after TRACON invoked contractual dispute resolution provisions asserting that I-Mab had breached its contractual obligations.

Key Points: 
  • I-Mab commenced arbitration in June 2020, after TRACON invoked contractual dispute resolution provisions asserting that I-Mab had breached its contractual obligations.
  • I-Mab initiated the arbitration seeking a declaration that they were not in breach of either agreement, and TRACON filed counterclaims soon thereafter.
  • Among other findings, the ICC tribunal deemed the TJ004309 trial complete as of January 2022, which entitled TRACON to $9.0 million plus interest, and awarded legal fees and costs to TRACON.
  • The award is made pursuant to a binding arbitration, and both agreements are now terminated.

TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 8, 2023
TCON, International, CT, TRACON, SAN, Doxorubicin, Research, Therapy, Patient, CD73, ORR, Fine chemical, Pharmaceutical industry, Cryptocurrency, Video game

“The significant progress we achieved in the fourth quarter sets up 2023 to be a potentially transformational year for TRACON,” said Charles Theuer, M.D., Ph.D., President and CEO of TRACON.

Key Points: 
  • “The significant progress we achieved in the fourth quarter sets up 2023 to be a potentially transformational year for TRACON,” said Charles Theuer, M.D., Ph.D., President and CEO of TRACON.
  • Research and development expenses for the fourth quarter of 2022 were $3.9 million, compared to $3.1 million for the fourth quarter of 2021.
  • General and administrative expenses for the fourth quarter of 2022 were $2.0 million, compared to $4.6 million for the fourth quarter of 2021.
  • Net loss for the fourth quarter of 2022 was $7.0 million, compared to $7.7 million for the fourth quarter of 2021.

Global Air Traffic Control (ATC) Market to Reach $13.5 Billion by 2027 at a CAGR of 8.4% - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 21, 2022
Transport, Air, ATC, ARTCC, Airport, Software, ATCT, Data collection, Communication, Region, TRACON, Automation, Air traffic control, COVID-19, MIND Technology, Inc., USD, Hardware, Growth, Brownfield land, Atmosphere of Earth, Saab AB, L3Harris Technologies, Atmosphere, Thales Group, Airline, Service

The Air traffic control (ATC) market is estimated to be USD 9.0 billion in 2022 and is projected to reach USD 13.5 billion by 2027, at a CAGR of 8.4% from 2022 to 2027.

Key Points: 
  • The Air traffic control (ATC) market is estimated to be USD 9.0 billion in 2022 and is projected to reach USD 13.5 billion by 2027, at a CAGR of 8.4% from 2022 to 2027.
  • Software and solutions: The dominating segment of the air traffic control (ATC) market, by the offering
    The Air Traffic Control (ATC) market has been segmented based on offering into hardware and software and solutions.
  • Automation: The fastest-growing and leading segment of the air traffic control (ATC) market, by application
    The air traffic management market is segmented based on application: communication, navigation, surveillance, and automation.
  • North American countries are awarding a number of contracts to major players of the air traffic control (ATC) market for the delivery of air traffic control (ATC) and related components, thus driving the growth of the air traffic control (ATC) market in the region.

Smart Airports Market worth $8.3 Billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, January 4, 2023
Cloud, ATC, Ecosystem, Equipment, Hardware, Commercial, RFID, B2B, Airport, Air traffic control, Cisco Systems, Research, Kratos Defense & Security Solutions, ARTCC, Endpoint, Stargate SG-1 (season 4), Enablement, LED, TRACON, Air travel, Honeywell, Daou Technology Inc., ATCT, L3Harris Technologies, Lighting, Growth, Organization, Amadeus IT Group, USD, Elevated railway, Intel Upgrade Service, Access control, GTM, IBM, Brownfield land, Forbes Global 2000, Conveyor belt, Software, Region, Directory Assistance Service, Siemens, Low-end market, PAPI, Renewable energy, Airline, Service, Geography, Maintenance

CHICAGO, Jan. 4, 2023 /PRNewswire/ -- The smart airports market size is projected to grow from USD 7.0 Billion in 2022 to USD 8.3 Billion by 2027, at a CAGR of 3.5% from 2022 to 2027 according to a new report by MarketsandMarkets™.

Key Points: 
  • CHICAGO, Jan. 4, 2023 /PRNewswire/ -- The smart airports market size is projected to grow from USD 7.0 Billion in 2022 to USD 8.3 Billion by 2027, at a CAGR of 3.5% from 2022 to 2027 according to a new report by MarketsandMarkets™.
  • The growing demand for advanced smart solution to cater the increased demand of air-passenger footfall to drive the market.
  • Based on End Market, Upgrades & Service segment is projected to lead the smart airports market during the forecast period.
  • Based on airport size, the medium segment is projected to lead the smart airports market during the forecast period.